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ABSTRACT A pivotal role is attributed to the estrogen-
receptor (ER) pathway in mediating the effect of estrogen
in breast cancer progression. Yet the precise mechanisms
of cancer development by estrogen remain poorly under-
stood. Advancing tumor categorization a step forward,
and identifying cellular gene fingerprints to accompany
histopathological assessment may provide targets for ther-
apy as well as vehicles for evaluating the response to
treatment. We report here that in breast carcinoma,
estrogen may induce tumor development by eliciting
protease-activated receptor-1 (PAR1) gene expression.
Induction of PAR1 was shown by electrophoretic mobility
shift assay, luciferase reporter gene driven by the hPar1
promoter, and chromatin-immunoprecipitation analyses.
Functional estrogen regulation of hPar1 in breast cancer
was demonstrated by an endothelial tube-forming net-
work. Notably, tissue-microarray analyses from an estab-
lished cohort of women diagnosed with invasive breast
carcinoma exhibited a significantly shorter disease-free
(P0.006) and overall (P0.02) survival of patients that
were positive for ER and PAR1, compared to ER-positive
but PAR1-negative patients. We propose that estrogen
transcriptionally regulates hPar1, culminating in an aggres-
sive gene imprint in breast cancer. While ER patients are
traditionally treated with hormone therapy, the presence
of PAR1 identifies a group of patients that requires
additional treatment, such as anti-PAR1 biological vehicles
or chemotherapy.—Salah, Z., Uziely, B., Jaber, M., Maoz,
M., Cohen, I., Hamburger, T., Maly, B., Peretz, T., B.-S,
R. Regulation of human protease-activated receptor 1
(hPar1) gene expression in breast cancer by estrogen.
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Breast cancer comprises a heterogeneous group of
diseases categorized into 3 major subtypes (1, 2).
Among these are tumors that possess estrogen recep-
tors (ERs) and progesterone receptors (PRs), breast
tissues that overexpress HER2, and triple-negative
breast cancer (TNBC) tissues. While the first 2 may well
respond to endocrine therapy or biologically targeted
anti-HER2 vehicles, TNBC is considered the most ag-
gressive subtype. Furthermore, TNBC lacks any detect-
able molecular signature and is the most poorly under-
stood. Consequently, a major challenge in breast
cancer is to identify molecular targets to possibly ex-
pand current categories and assist in determining treat-
ment.
While the human mammary gland is highly depen-
dent on estrogen (E2) for normal growth and mainte-
nance (3–5), ligation of E2 to ER, a nuclear transcrip-
tion factor, is the driving force in breast cancer
progression (6). E2-bound ER serves as a potent transcrip-
tion factor for the induction of novel genes downstream that
are important for normal cellular function and tumor
growth, independent of proliferation (7–10). These down-
stream genes may consequently become central targets in
breast cancer therapy (11). The main dogma for transcrip-
tional regulation by E2 involves the following steps: binding
of E2 to ER to initiate receptor phosphorylation, receptor
dimerization, and association of the ligand-ER complex with
binding motifs in the promoter of target genes. Concomi-
tantly, E2-bound ER favors the recruitment of coactivators
that enhance its transcriptional activity. In fact, the coregu-
lators serve as a fine-tuning device for receptor transcrip-
tional activity. Several coregulators have been implicated in
cancer, most notably AIB1 (SRC3), which is overexpressed
in the majority (two-thirds) of all breast cancers.
The ER signaling pathway in breast cancer is thought
to be regulated also outside the nucleus, initiated at the
cell membrane via crosstalk with receptor tyrosine
kinases, including epidermal growth factor receptor
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(EGFR or HER2/Neu) and insulin-like growth factor
receptor IR (12–14). This might be a mode of ER
activation in the E2-resistance pathway. These receptor
kinases activate signaling pathways, culminating in the
phosphorylation of ER as well as its coactivators and
corepressors at multiple sites and influencing their
specific final function (15).
Protease-activated receptor 1 (PAR1), a G-protein-
coupled receptor (GPCR), is the first and prototype
member of the mammalian PAR family that comprises
4 genes (16, 17). While a well-known classical observa-
tion points to a tight link between hyperactivation of
the coagulation system and cancer malignancies, the
molecular mechanism that governs procoagulant tu-
mor progression remains poorly defined (18–20).
There is correlation between levels of hPar1 expression
and breast cancer progression in both clinically ob-
tained biopsy specimens and a wide spectrum of differ-
entially metastatic cell lines (21–24). PAR1 is associated
with breast cancer malignancy. Its expression correlates
with the aggressiveness of human breast carcinoma cell
lines, and there is increased expression of the hPar1
gene and protein in human breast tumors when com-
pared with corresponding normal tissues (21). Mam-
mary gland tumors produced by MCF7 breast carci-
noma cells, genetically engineered to overexpress
either wild-type (WT) full-length hPar1 cDNA or a
superactive form of hPar1, were considerably larger and
more vascularized when compared with the truncated
form devoid of the cytoplasmic tail or mock-injected
cell-producing tumors (25). This observation indicates
that PAR1 is capable of eliciting mammary tumors in a
tight association with PAR1-driven signaling. Conse-
quently, we wondered whether there is hormonal reg-
ulation of hPar1 gene expression in the context of
breast tissues.
In the present study, we investigated E2 regulation of
PAR1 in breast carcinoma and established its functional
effect. A shorter disease-free survival (DFS; P0.006),
as well as overall survival (OS; P0.026), were observed
in ER and PAR1
 women compared with ER but
PAR1
 patients from a tissue microarray of an estab-
lished cohort of individuals with invasive breast carci-
noma. This outcome identifies PAR1 as part of an
aggressive gene imprint. Collectively, our data suggest
transcriptional regulation of hPar1 by E2-bound ER.
Noticeably, the presence of PAR1 may contribute to
decisions on treatment. While ER women receive
hormone treatment, the presence of PAR1 identifies a
group that may also need either anti-PAR1 biological
vehicles (currently emerging in the market) or chemo-
therapy.
MATERIALS AND METHODS
Cells
MCF-7 and T47D cells (American Type Culture Collection,
Manassas, VA, USA) were grown in RPMI 1640 supplemented
with 10% fetal calf serum, l-glutamine, penicillin, and strep-
tomycin. Steroid-depleted cell culture medium was RPMI
1640 phenol red-free medium supplemented with 10% char-
coal-stripped fetal bovine serum. Bovine aortic endothelial
cells (BAECs) were cultured in DMEM (with glucose, 1
mg/ml) supplemented with 10% calf serum and bFGF (26).
RNA extraction and RT-PCR
Total RNA was prepared using TRI reagent (Molecular
Research Center, Cincinnati, OH, USA) as described by the
manufacturer. PCR primers were as follows: hPar1, upstream
5-GCCAGAATCAAAAGCAACAA-3 and downstream 5-
GAGATGAATGCAGGAAGTTGTTT-3; GAPDH, upstream
5-CCACCCATGGCAAATTCCATGGCA-3 and downstream
GADPH: 5-TCTAGACGGCAGGTCAGGTCCACC-3.
PCR products were separated on a 1.5% agarose gel stained
with ethidium bromide and visualized under ultraviolet light.
Activation of PAR1
PAR1 was activated by the TFLLRNPNDK peptide, a selective
PAR1 agonist, or thrombin (1 U/ml).
Transfection and luciferase (LUC) expression assay
MCF-7 cells, grown for 48 h in steroid-depleted cell culture
medium to 60–80% confluency, were transfected with 2 g of
the hPar1 promoter fragment plasmid DNA Poluc-HTR/-4.1
(F1; kindly provided by Dr. Marschall S. Runge, University of
North Carolina at Chapel Hill, Chapel Hill, NC, USA) or
empty expression plasmid (2 g), and CMVgal (0.3 g) in
FuGene-6 transfection reagent (Roche Diagnostics Co., Indi-
anapolis, IN, USA). After 48 h, the cells were either treated
for the indicated periods of time with E2 (Sigma-Aldrich, St.
Louis, MO, USA) or not, and then lysed in 0.1 ml of lysis
buffer (Promega, Madison, WI). Luciferase activity was mea-
sured as described previously (27).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts (NEs) were prepared as described previously
(27, 28). Complementary oligonucleotide probes were syn-
thesized (Metabion, Martinsreid, Germany) for the hPar1
putative estrogen-response element (ERE) sites according to
GenBank accession number U63331: P1, 5-agatgcgcaggT-
GACCcccg at site2081; P2, 5-ccctGTCActacatcataa-3 at site
2150; and P5, 5-ccctGTCActacatcataa-3 (R) at site 2654.
The C consensus sequence ERE is 5-cagGTCAtcaTGACCtg-
3. Underscored sequences indicate the seed sequence of
ERE (uppercase letters). Lowercase letters indicate a muta-
tion inserted into the sequence. For competition experi-
ments, 1- to 100-fold of unlabeled double-stranded oligonu-
cleotide was added 15 min prior to incubation. The oligos for
P3 and P4 are as follows: P3, 5-ttagcgaaaactTGAaCtttt-3; P4,
5-gcggccgtCTcGACCctcct-3. Mutants for each of the oligos
are as follows: mutant P1, 5-agatgcgcaggtACCccg-3; mutant
P2, 5-tta tgatgtagTtACaggg-3; mutant P3, 5-ttagcg aaaactT-
tAACttt-3; mutant P4, 5-gcggccgtCTcGtCCctcct-3; mutant
P5, 5-gaagctgttcagTtACtCac-3.
Chromatin immunoprecipitation (ChIP) and PCR analysis
MCF-7 cells were grown for 48 h in serum-free starvation
medium and then either left untreated or treated with E2
(108 M) for 2 h. ChIP was performed as described previously
(27, 29). Following treatment, MCF-7 cells were fixed with
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formaldehyde (to a final concentration of 1%) at room
temperature for 10 min to cross-link histone proteins to DNA.
Glycine was then added (to a final concentration of 0.125 M)
to the plates to quench formaldehyde. Soluble chromatin was
isolated and sonicated. Samples were then centrifuged at
13,000 rpm for 10 min, and the supernatant was collected.
For the immunoprecipitation step, 10 g of antibodies,
prebound to protein A/G Sepharose beads, was added to 500
l of the purified chromatin sample and incubated overnight
at 4°C. Ab-immunocomplexed DNA was then recovered by
phenol/chloroform extraction, ethanol precipitation, and
resuspension in TE. PCR primer sets were designed to overlap
and span the ERE binding sites of the hPar1 promoter. ERE
primer set I: forward, 5-actgtcgacgtctccacacatc-3, and re-
verse, 5-tgtaatccccgcactttaggag-3; set II: forward, 5-tgtaatc-
cccgcactttaggag-3, and reverse, 5-ccactgtcgacgtc tccacatccc-
3. These primers were first evaluated using the Par1-Luc
construct as a DNA template. Semiquantitative PCR was then
performed using the Titanium TaqPCR kit (Clontech Labo-
ratories, Palo Alto, CA, USA). Amplification was carried out
for 35 cycles (28 cycles for unprecipitated chromatin input
lanes) with denaturation at 94°C for 1 min, annealing at 58°C
for 30 s, and extension at 72°C for 1 min. PCR products were
separated on a 2% agarose gel.
ELISA
Quantification of the levels of VEGF secreted by hPar1 cells
was carried out by ELISA (Quantikine/human VEGF; R&D
Systems, Minneapolis, MN), performed according to the
manufacturer’s instructions with anti-VEGF neutralizing Abs
C20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Calcium flux assay
Intracellular Ca2 flux was measured in MCF-7 cells labeled
with fura-2AM (a cell-permeable acetoxymethyl ester form of
Fura-2; eBioscience, San Diego, CA, USA) by the ratio of
fluorescence excitation intensity at 340/380 nm on a Fluro
Scan Ascent SL (Thermo Electron Corp., Waltham, MA,
USA).
Three-dimensional (3D) tube-forming assay
The assay was performed as described previously (24). Briefly,
type I collagen matrix gel was obtained by simultaneously
raising the pH and ionic strength of the collagen solution.
Collagen was then used to coat 24-well plates (0.3 ml/well).
After polymerization of the collagen at 37°C for 0.5 h, BAECs
(2104 cells/0.5 ml/well) were added to each well. Collagen
solution (0.4 ml) was carefully placed on top of the cells. After
the gel was formed, 0.4 ml of conditioned medium (CM)
from the different treatment was added and replaced with
fresh medium every other day. Tube formation and align-
ment of BAECs were visualized by phase microscopy at d
8–10. The morphometric analysis used to evaluate tube
formation was performed as follows. Briefly, every well in a
given plate (per treatment) was independently evaluated by 2
investigators (M.J. and R.B.). Discrepancies were resolved by
simultaneous reexamination of the wells by both investigators
using a double-headed microscope. The microscope was
calibrated with a micrometer slide before each measurement.
Ten fused cells/field were selected, and 50 fused cells/
treatment case were assessed. Four microscopic fields were
screened. Data are reported as means  sd, and P values were
determined by 	2 test; values of P 
 0.05 were considered
significant. The data are representative of 4 independent
experiments performed in triplicate.
Tissue microarray construction, immunostaining, and
statistics
Formalin-fixed, paraffin-embedded breast carcinoma tissues
from 299 nonselected patients with invasive breast carcinoma
(220 ductal, 33 lobular, 13 ductal  lobular, 7 medullary, 3
mucinous, 9 DCIS, and 14 DCIS  microinvasion) were
obtained from the Department of Pathology, Hadassah Med-
ical Center (Jerusalem, Israel). The use of these specimens
and data in research was approved by the Ethics Committee
of the Hadassah Medical Center. Sections (5 m) stained with
hematoxylin and eosin (H&E) were obtained to confirm the
diagnosis and to identify representative areas of the speci-
men. From these defined areas, 3 tissue cores with a diameter
of 0.6 mm were taken with a manual tissue arrayer MTA-1
(Beecher Instruments, Sun Prairie, WI, USA) as described
previously (30, 31). From each specimen, 3 tissue cores with
a diameter of 0.6 mm were taken from the different regions
of the tumor and arrayed in triplicate on a recipient paraffin
block (28). Sections of 5 m of the recipient blocks were cut
and placed on charged polylysine-coated slides. Immunode-
tection of PAR1 was done as described previously (25) with
minor modifications. Briefly, sections of the tissue array
blocks were deparaffinized and rehydrated. Tissue was then
incubated in 3% H2O2, denatured by boiling (3 min) in a
microwave oven in citrate buffer (0.01 M, pH 6.0), and
blocked with 10% goat serum in PBS. Sections were incubated
with polyclonal anti-PAR1 antibody raised against a peptide
(NH2-CLLRNPNDKYEPFWED-COOH) representing an inter-
nal sequence downstream of the PAR1 cleavage site, for activa-
tion. We also used polyclonal rabbit anti-PAR1 antibody directed
against a synthetic peptide (NH2-KSSPLQKQLPAFISC-COOH)
corresponding to an internal sequence of PAR1 cleavage site,
downstream of the above-mentioned peptide. The antibody was
diluted 1:100 in 10% goat serum in PBS. Control slides were
incubated with 10% goat serum alone. Color was developed
using the Zymed AEC substrate kit (Zymed Laboratories, Bur-
lingame, CA, USA) for 10 min, followed by counterstaining with
Mayer’s hematoxylin. For immunodetection of ERa and PR,
monoclonal antibodies NCL-L-ER 6F11 and NCL-PGR-312, re-
spectively, were used (Novocastra, Newcastle upon Tyne, UK).
Slides were visualized with a Zeiss axioscope microscope (Carl
Zeiss, Oberkochen, Germany) and manually read by an expert
pathologist (B.M.). Tumors were considered positive for ER/PR
if nuclear staining was seen in 10% of the tumor cells. To
define a tumor as PAR1
, staining of 25% of the tissue was
considered positive on the basis of an initial overview of the cases
to improve signal-to-noise ratios. We also tested additional, even
stricter, cutoffs (i.e., 50%, 75%) of tumor cells staining for
PAR1. 	
2 tests were done to study the PAR1 expression in ER

immunohistochemical results, using SPSS software (SPSS Inc.,
Chicago, IL, USA).
RESULTS
The hPar1 gene regulatory region contains 5
consensus EREs
A bioinformatic search of the regulatory region of hPar1
(U63331, 4.1 kb in size; ref. 27) revealed 5 candidates
for EREs. The sequences of these putative ERE are
1853 to 1870, 5-agatgcgcaggTGACCcccg-3; 2078
to 2096, 5-ccctGTCActacatcataa-3 (R); 2159 to
2169, 5-ttagcgaaaacTGAaCttt-3; 2281 to 2300,
5-aggagGGTCgagacggccgc-3 (R); 2351 to 2368,
5-ccctGTCActacatcataa-3, shown in Fig. 1A. To exam-
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Figure 1. E2 treatment induces hPar1 promoter activity and increases its expression. A) Scheme of hPar1 regulatory region and
the potential ERE sequences identified. Bi) Kinetics of E2-treated MCF-7 cells. Two concentrations (10
8 and 109 M) of E2 were
applied for various time periods as indicated, followed by RNA isolation and RT-PCR analysis for levels of PAR1. While a marked
enhancement in PAR1 level is seen by 2 h of 10
8 M treatment and remains up to 24 h, no effect is seen by 2 h at 109 M. At
this concentration, an elevated level of PAR1 is observed after 4 h treatment and continuously up to 24 h. Similar data were
obtained when T47D cells were analyzed (data not shown). Data are representative of 5 experiments. Bii) Specificity of E2
treatment on PAR1 levels. RT-PCR analysis of hPar1 performed on RNA isolated from MCF-7 and T47D cells before and after
E2 treatment (2 h, 10
8 M) shows induced hPar1 expression (as demonstrated in Bi). This induction was specifically inhibited
in the presence of ICI182,780, a potent E2 inhibitor, while application of ICI alone had no effect on PAR1 levels. Data are
representative of 3 experiments. Biii) Histogram represents band intensity after normalization with the GAPDH housekeeping
gene. C) PAR1 protein levels following E2 treatment: Western blot analysis of MCF-7 and MDA-231 cells before and after E2.Level
of cell lysate loading is verified by -actin levels. An increase in PAR1 levels in MCF-7 cells is obtained at 10
8 M E2. In contrast,
no effect on PAR1 levels is observed when MDA-231 cells lacking ER were similarly treated. Data are representative of 3
experiments. D) E2 regulation of hPar1-LUC-promoter activity. MCF-7 cells were transiently transfected with hPar1-LUC reporter
(continued on next page)
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ine whether E2 modulates hPar1 expression, we used
semiquantitative reverse-transcription PCR, Western
blot, and hPar1-driven LUC promoter activity to esti-
mate hPar1 mRNA expression in ER
 breast carcinoma
cells. As shown in Fig. 1Bi, a marked increase in hPar1
RNA levels in MCF-7 cells was obtained following 2 and
6 h of E2 treatment with 10
8 and 109 M, respectively.
This high level was observed up to 24 h at both
concentrations. The specificity for E2 regulation was
demonstrated in 2 cell lines (T47D and MCF-7; Fig.
1Bii), in which the increased hPar1 level was inhibited
by applying ICI 182,780, an E2 antagonist (32). While
1  107 M ICI 182,780 alone had no effect on the
endogenous hPar1 level, in the presence of E2 it com-
pletely abolished the induced hPar1 mRNA expression
in both MCF-7 and T47D cell lines (Fig. 1Bii). Western
blot analyses verified the increase in PAR1 protein levels
following E2 treatment (10
8 M &109 M, 2 h) in ER
MCF-7, as well as in T47D cells (data not shown), but
not in MDA-231 cells, which lack ER (Fig. 1C). The
responsiveness of the hPar1 promoter to E2 was shown
following transient transfection of hPar1-driven LUC
promoter and subsequent analysis of its activity. As seen
in Fig. 1D, LUC-hPar1 promoter activity was increased
4-fold (P
0.005) by E2 treatment (2 h, 10
8 M). A
similar increase in LUC-hPar1 promoter activity was
obtained at 109 M E2 treatment for longer periods of
incubation (e.g., 6 h; data not shown). This elevated
LUC-hPar1 promoter activity was completely blocked by
the E2 inhibitor, ICI (Fig. 1D). MCF-7 cells treated with
E2 (representing elicited PAR1 levels) exhibit greater
sensitivity to thrombin as compared with cells prior to
E2 treatment. This is demonstrated by the Ca
2 flux
assay performed in MCF-7 activated by thrombin before
and after E2 application. As shown in Fig. 1E, a marked
elevation of nearly 5-fold in the Ca2 response was
obtained in the E2-treated cells in thrombin concentra-
tion range analyzed (i.e., 100–750 nM).
Binding properties of hPar1-ERE consensus motifs
To determine which of the candidate E2-consensus sites
are functional and capable of binding protein (e.g.,
ligated ER), we prepared NEs of ER MCF-7 cells. In
parallel, we end-labeled the oligonucleotides represent-
ing EREs in the hPar1 promoter corresponding to hPar1
ERE 1, 2, and 5 (designated as P1, P2, and P5; see
Fig. 3C). As shown in Fig. 2, incubation of 32P-labeled
oligos with E2 resulted in specific DNA-protein com-
plexes. Significant binding was observed in the oligo
representing C (i.e., 5-caggtcatcatgacctg-3), the
known consensus binding motif for ERE, serving as a
positive control (Fig. 2, lane 4), as well as in P1 (Fig. 2,
lane 8), P2 (Fig. 2, lane 10), and P5 (Fig. 2, lane 12).
The binding is specific, since no binding was observed
when the NE was not present in the assay (Fig. 2, lanes
1, 3), when NE of cells that do not express ER (e.g.,
DU-145 prostate cancer cells; Fig. 2, lane 14) was
applied, or prior to E2 treatment (Fig. 2, lane 2).
Significant binding was observed after E2 treatment
(Fig. 2, lanes 4, 8, 10, 12). Competition for binding
between protein and DNA following E2 treatment, in
the presence of excess unlabeled oligos representing
P1, P2, or P5 (Fig. 2, lanes 9, 11, 13), showed effective
inhibition of the ligated ER. Mutated oligonucleotides
representing the 5 ERE motifs found in the hPar1
promoter were prepared as described in Materials and
Methods. EMSA revealed that excess cold amounts
(1000) of the mutated hPar1-EREs failed to compete
with the corresponding WT oligonucleotide of each of
the individual ERE site (data not shown). Mutants of P3
and P4 did not have any effect, since their labeled
oligos did not bind in the first place (see below for
nonfunctional ERE sites). Moreover, utilizing excess
cold amounts of P1, P2, or P5 ERE oligos effectively
inhibited the binding of the consensus C-ERE (Fig. 2,
lanes 5, 6, 7). No binding of P1, P2, or P5 was observed
prior to E2 treatment (data not shown). No specific
interaction was seen when oligos representing ERE 3
and ERE 4 (termed P3 and P4, respectively; outlined
sequence shown in Fig. 3C) were applied, regardless of
E2 treatment (data not shown). Application of anti-ER
antibodies (anti-ER, D-12; Santa Cruz Biotechnology)
to the binding assay and following E2 treatment effi-
ciently abrogated the binding of ER to each of the
oligos tested, regardless of whether the consensus motif
or the hPar1-representing ERE motifs were tested (Fig.
2, lanes 15, 17, 19, 21). This outcome further demon-
strates that the anti-ER antibody recognizes the epitope
in ER that interacts with the EREs present in the hPar1
promoter, thereby interfering with these associations. While
it is common to obtain a bandshift effect, we repeatedly
observed band abrogation, which is not often obtained.
Control IgG had no effect on the binding properties (Fig. 2,
lane 23). This outcome strongly suggests that the 3 ERE
motifs located within the hPar1 regulatory sites are functional
and capable of interacting in a sequence-specific manner
with the cognate ER.
We next asked whether the E2-responsive regions
identified in the hPar1 promoter physically interact in
or empty vector plasmids and either treated or not with 108 M E2 for a period of 2 h. A marked up-regulation in LUC activity
was obtained during this time frame at a concentration of 108 M, but not at 109 M. The specificity toward E2 regulation is
shown by application of the inhibitor, ICI. While ICI itself did not have any effect on hPar1-LUC activity, it potently inhibited
the E2-elicited hPar1-LUC activity. Luciferase activity was normalized to -gal activity as a control for transfection efficiency.
Values are means  sd (n6). Data are representative of 5 experiments. E) Ca2 flux signaling of thrombin-treated MCF-7
cells before and after E2 treatment. MCF-7 cells were seeded onto 96-well plates and were serum deprived for 24 h before E2
treatment. E2-treated cells (2 h) were loaded with Fura2AM (5 M, 60 min) in Na-HEPES-buffered saline at pH 7.4. Cells were
then treated with thrombin at the indicated concentrations and monitored every 30 s. Fluorescence was measured by a dual
wavelength excitation fluorimeter at 340 and 380 nm (510 nm for emission) in a Fluro Scan Ascent SL (Thermo Electron).
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vivo with ER. ChIP analysis on MCF-7 cells was per-
formed before and after E2 treatment. Chromatin was
isolated and immunoprecipitated with anti-ER anti-
bodies. DNA obtained from the immunoprecipitated
chromatin was amplified utilizing 2 sets of primers
directed to encompass ERE motifs within the hPar1
promoter. The signal level obtained in the noncom-
plexed chromatin PCR confirmed that equal amounts
of DNA had been loaded. A specific increase of3-fold
in the presence of E2 as compared with untreated cells
was obtained. When antibody directed to an irrelevant
protein (Flt-1, a cell surface receptor) or control IgG
was used to immunoprecipitate the chromatin from the
cell lysates (before and after E2 treatment), minimal
levels were observed, which were not affected by E2
treatment (Fig. 3A). As controls, primers were planned
to amplify regions outside the ERE-hPar1 motifs. These
primers were directed to amplify an area located down-
stream to the ERE in the 5 promoter site, as well as to
recognize a site within the 3hPar1 gene. While both sets
of primers effectively recognized the promoter cDNA
construct or the 3 region of the gene, respectively, they
failed to amplify DNA obtained from the immunocom-
plex (Fig. 3B). These results further validate a direct
and specific association between E2-ligated ER and the
ERE motifs found in the 5 regulatory region of hPar1.
E2 induces PAR1-associated breast cancer
angiogenesis: elicited endothelial tube-forming
network in 3D cultures
We previously demonstrated that activation of PAR1
markedly augments the expression and function of
VEGF mRNA splice forms, as determined by in vitro
assays for endothelial tube alignment (24). We exam-
ined whether treatment with E2 (i.e., 10
8 M, 2 h) of
either MCF-7 or T47D cells expressing ER is capable of
eliciting the expression of functional VEGF. Indeed, as
shown in Fig. 4A, E2 treatment (i.e., 2 h) before and
after PAR1 activation (i.e., 6 h) enhanced the levels of
VEGF165.
To determine whether the increased levels of VEGF
mRNA and protein induced by hPar1 gene correspond
to increased levels of functional protein, we collected
CM from either untreated or E2-treated MCF-7 cells,
before and after PAR1 activation. To establish how
much VEGF is produced and secreted, VEGF-CM was
quantitated by ELISA. In CM (up to 30 h) derived from
control cells (no PAR1 expression), there was no signif-
icant VEGF release (
18 pg/ml). In 6- to 8-h CM
derived from MCF-7 cells following E2 treatment and
PAR1 activation, VEGF levels were 1112  18 pg/ml
(P
0.01), compared with 311.2  22 pg/ml in nonac-
tivated MCF-7 cells treated with E2. Thirty-hour CM
from nonactivated MCF-7 cells treated with E2 con-
tained 989  112.7 pg/ml VEGF; on PAR1 activation,
VEGF release was increased to 3996.3  221.4 pg/ml
(P
0.005). Levels of VEGF in the CM of nonactivated
MDA-435 were 1521 112.8 pg/ml and following PAR1
activation increased to 4996.3  pg/ml (P
0.05). We
employed an endothelial tube-forming assay to assess
the VEGF activity present in the CM. BAECs were
embedded in a 3D collagen (type I) mesh, and the
extent of tube-forming network was evaluated after
application of the various CMs (24). Although low
Figure 2. Identification of functional EREs in
hPar1 promoter. NEs of MCF-7 cells and
32P-
labeled ERE oligos were used in an EMSA
analysis. E2 treatment enhanced binding of
either a known ERE sequence positive control
(C) or hPar1-ERE P1, P2, and P5 oligos (lanes 4,
8, 10, and 12, respectively) as compared with
competition in the presence of excess unla-
beled oligos. Competition with excess unla-
beled ERE P1, P2 or P5 (lanes 5, 6, and 7,
respectively) inhibited the binding of 32P-la-
beled ERE consensus sequence oligos C (lane
4). Likewise, competition with excess unlabeled
hPar1 ERE P1 oligo inhibited the binding of
32P-labeled ERE P1 (lanes 8 and 9, respec-
tively). Competition with excess unlabeled
hPar1 ERE P2 oligo inhibited binding of
32P-P2
oligo, while excess cold P5 inhibited the bind-
ing of 32P-P5 oligo (e.g., lanes 10 vs. 11, and 12
vs. 13, respectively). Control ERE showed no
binding when either no NE (lanes 1, 3) or NE
without E2 treatment (lane 2) was applied.
Similarly, when NE of DU-145 cells that do not
express ER was used, no binding was observed
(lane 14). When anti-ER antibodies were ap-
plied to the binding system, inhibition of bind-
ing of consensus (lane 15 vs. 16) and hPar1-
EREs P1, P2, and P5 (lanes 17 vs. 18, 19 vs. 20,
and 21 vs. 22, respectively) were obtained. As a
control, when IgG was applied to the binding system, no effect was observed for either 32P oligos C (lane 23) or 32P oligos P1,
P2, or P5 (data not shown). Data are representative of 3 experiments.
2036 Vol. 26 May 2012 SALAH ET AL.The FASEB Journal  www.fasebj.org
vascular branching activity was obtained with untreated
control CM, with or without thrombin treatment, a
more complex network was observed following activa-
tion of PAR1 that was overexpressed by E2-treatment in
the ER-expressing MCF-7 cells (Fig. 4Bi). One should
keep in mind that VEGF alone is a target for ER
transcriptional regulation (33). EREs are found within
the VEGF promoter; therefore, E2 treatment alone may
induce VEGF levels. However, the specificity for hPar1-
enhanced VEGF in our experimental system was dem-
onstrated by applying CM collected from cells infected
with an siRNA-hPar1 lentiviral vector, in either MDA-
435 metastatic breast cancer cells that overexpress hPar1
(Fig. 4BiVIII) or in MCF-7 cells that were treated with E2
(Fig. 4BiIV). To show that activation of PAR1 induces
VEGF, application of anti-VEGF-neutralizing Abs C20
(Santa Cruz Biotechnology) was carried out, leading to
the abrogation of tube network formation (Fig. 4BiVI).
These data demonstrate that E2 treatment of ER-ex-
pressing MCF-7 cells elevates PAR1 expression to gen-
erate functional angiogenesis.
Functional consequences of PAR1 expression in
clinical samples of breast carcinoma
The molecular characterization of breast cancer sub-
types has led to significant progress in treating this type
of malignancy. Advancing tumor categorization and
identifying cellular imprints to accompany histopatho-
logical assessment may provide cellular targets for
therapy, as well as effective vehicles to evaluate the
response to a given treatment. Immunohistochemical
analyses were used to evaluate the profile of PAR1
overexpression in clinically obtained breast cancer bi-
opsy specimens. A tissue microarray obtained from an
established cohort of 299 women diagnosed (Table 1)
with invasive breast carcinoma was immunostained for
Figure 3. ChIP assay to demonstrate the in vivo interaction between ER and the hPar1-ER consensus site. A) DNA fragments
immunoprecipitated with the indicated antibodies were purified, and the regions containing the ERE proposed sites were
amplified by PCR. An equal amount (input) of DNA was applied. PCR products generated using either hPar1 promoter primers
or GAPDH primers to amplify from immunoprecipitated DNA before () and after () E2 treatment of MCF-7. GAPDH
primers, control IgG, and nonrelative ( Flt-1) antibody were used as controls for nonspecific immunocomplexes. Results are
representative of3 independent experiments. B) As controls, a set of primers was designed to amplify regions outside the ERE
motifs. One set of controls was designed to amplify a region located downstream to the ERE in the 5 promoter site (5 UTR).
The second set was designed to recognize a region in the 3 end of hPar1. Neither of the primers gave a product when amplifying
DNA from the immunocomplex. These controls emphasize the specificity of the hPar1-ERE located at the 5 regulatory region
of the gene. C) 5 flanking sequences of PAR1 promoter and proposed ERE motifs are shown. Functional and nonfunctional
EREs are highlighted, as are the sequences of the 2 sets of primers used. Data are representative of 3 experiments.
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Figure 4. E2 treatment of MCF-7 cells elicits PAR1-induced functional VEGF. A) Semiquantitative RT-PCR for VEGF165. Analyses of RNA
isolated from MCF-7 cells demonstrate increased levels of VEGF165 following E2 treatment (i.e., 2 h, 10
8 M) alone, and long-term PAR1
activation (6 h) by thrombin or the ligand-activating peptide, TFLLRNPNDK (data not shown). No expression of VEGF165 is seen in MCF-7
cells prior to E2 treatment. Bi) Endothelial cell tube-forming assay. CM from either MCF-7 cells before and after E2 treatment or MDA-435
expressing high PAR1 levels increases the complexity of cell tube formation. Cultures of endothelial cells in a 3D collagen type I matrix were
grown with CM from nonmetastatic MCF-7 cells expressing very little or no hPar1, before and after E2 treatment and PAR1 activation (I–III),
or activated MDA-435 cells (VII, VIII). The importance of PAR1 in the process is demonstrated following silencing of hPar1 after infection
with siRNA-hPar1 either in MCF-7 cells (IV, V) or MDA-435 cells (VIII). The effect of VEGF is shown by incubating CM from E2 treatment
as well as PAR1 activation with neutralizing anti-VEGF Abs C20 (VI; Santa Cruz Biotechnology). Bii) Morphometric analysis used to evaluate
tube formation was performed as explained in Materials and Methods. Briefly, each well in a given plate (per treatment) was independently
evaluated by 2 investigators (M.J. and R.B.). Discrepancies were resolved by simultaneous reexamination of the wells by both investigators
using a double-headed microscope. The microscope was calibrated with a micrometer slide before each measurement. Ten fused cells/field
were selected, and 50 fused cells/treatment case were assessed. Four microscopic fields were screened. Error bars  means  sd;
difference between groups was determined by 	2 test. Data are representative of 4 independent experiments performed in triplicate.
C) Silencing of hPar1 by siRNA construct. Infection of siRNA-hPar1 in MDA-435 cells leads to the inhibition of PAR1 protein and RNA. These
data are representative of 3 experiments.
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PAR1 (Fig. 5) and ER/PR (data not shown). While the
frequency of ER positivity was 62% (176 tumors), and
PR was expressed in 44 (15%) tumors, PAR1 expression
was found in 76% of all the tumors. No PAR1 expres-
sion was detected in any of the 5 control specimens of
nonmalignant breast tissues (Fig. 5, representative con-
trol staining).
	2 analysis of DFS of the ER patients (5 yr retro-
spectively) among the tissue microarray cohort of pa-
tients that overexpress or do not overexpress PAR1
showed the following outcome. A markedly significant
(P0.006) difference in the DFS in women that over-
express both ER and PAR1 represented a distinctly
shorter DFS (median not reached) compared with
patients who were ER but negative for PAR1 (Fig. 5B).
Likewise, a shorter OS was observed in ER and PAR1

patients, compared with ER and PAR1
 (P0.021)
patients. These observations strengthen the concept
that PAR1 may account for part of a highly malignant
gene signature in breast carcinoma.
DISCUSSION
With the goal of gaining mechanistic insights into PAR1
and E2 action in the etiology of breast cancer progres-
sion, we examined functional consequences of PAR1
expression in clinical tissue microarray settings and
biochemically characterized E2 regulation of hPar1 ex-
pression. An ongoing challenge is to identify molecular
means to assist in evaluating the degree of response to
a given therapy. Five-year retrospective analyses of ER
patients that express PAR1 resulted in a significantly
shorter DFS and OS compared with ER but PAR1

patients. This could aid in optimizing our approach to
personalized care whereby genetic print/s may im-
prove the prediction of the course of disease and
response to treatment. Indeed, gene signature might
complement the traditional pathological assessment in
evaluating tumor behavior. Similarly, Oncotype Dx, a
gene profile that has been recently developed for
women with hormone receptor-positive disease, is a
good example of such refinement and is part of an
oncologist’s practice today (34). Accordingly, while a
low score is consistent with hormone therapy, a high
score indicates that the addition of treatment such as
chemotherapy may be required. The presence of PAR1
may tilt the score or stand on its own when making a
decision on treatment. In addition, despite early detec-
tion that is more common today, there are still small
tumors (e.g., early detection) that can cause death. In
these tumors, newly emerging biological biomarkers
may greatly assist in making a treatment decision.
The regulatory sequence of hPar1 has been cloned
(35), enabling the identification of specific transcrip-
tion factors (i.e., Sp1, Egr-1), as well as tumor suppressor
genes (i.e., AP2 and p53), as potent regulators of the
hPar1 gene (27, 29, 36). Yet the molecular pathway
responsible for enhanced hPar1 overexpression in de-
veloping tumors as compared with normal tissues of the
same origin remains poorly understood.
Transcriptional regulation plays a central role in
hPar1 tumor-associated gene overexpression. We have
demonstrated that Egr-1 acts at the transcriptional level
to noticeably induce hPar1 gene levels in prostate
cancer (27). Here p53, a nuclear transcription factor
and a well-studied tumor suppressor gene, was also
shown as a regulator of hPar1 gene expression and
function (29). While an inverse correlation exists be-
tween WT p53 expression and hPar1, the mutant p53
forms, representing either loss of p53 or impaired
function, directly correlate with hPar1 overexpression in
cancer (29). Likewise, Tellez et al. (36) demonstrated
an inverse correlation between the expression of acti-
vator protein-2 (AP-2) and the overexpression of PAR1
in metastatic melanoma. In contrast, a direct correla-
tion has been established between the expression of
specificity protein 1 (Sp1) and aggressive melanoma
(36). Altogether, these observations strengthen the
notion that specific transcription factors and tumor
suppressors may delicately regulate the overexpression
of the hPar1 gene in a given cancer context.
Promoter analyses have identified the functional
ERE regions in the hPar1 regulatory region by employ-
ing EMSA examinations, which point to the regions
corresponding to P1, P2, and P5 capable of specifically
TABLE 1. Characteristics of study population (n299
subjects): clinical and pathological aspects
Parameter Value
Criteria
Age (yr) 49 (20–82)
Tumor size (cm) 2 (0.2–9)
Tumor type n (%)
IDC 220 (73.5)
ILC 33 (11)
IDC  ILC 13 (4.3)
DCIS 9 (3.0)
DCIS  microinvasion 14 (4.6)
Mucinous 3 (1.0)
Medullary 7 (2.3)
Lymph node status n (%)
LN-negative 159 (53.1)
LN-positive 120 (40.1)
Grade n (%)
1–2 161 (54.5)
3 134 (45.4)
Total valid 295
ER n (%)
Negative 105 (37.2)
Positive 177 (62.7)
Total valid 282
PR n (%)
Negative 235 (84.2)
Positive 44 (15.7)
Total valid 279
TN n (%) 95 (34.79)
Total valid 273
Values are median and range for criteria; number of cases and
percentage for all other parameters. DCIS, ductal carcinoma in situ;
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; TN,
triple negative.
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associating with ER present within the NEs in the assay.
ChIP analysis confirmed physical in vivo association
occurring between the functional ERE motifs and ER.
It remains to be determined whether the observed E2
stimulation of hPar1 may be attributed in part to
interplay between the ER and the hPar1-inducing tran-
scription factors found to regulate hPar1 transcriptional
activity.
PAR1 is tightly associated with breast cancer tumori-
genesis, as demonstrated by the orthotopic inoculation
of cells expressing hPar1 into mouse mammary glands
in vivo. Large and highly vascularized tumors were
generated when MCF-7 cells were genetically engi-
neered to overexpress either WT hPar1 or Y397Z hPar1,
with persistent signaling. In contrast, cells overexpress-
ing the truncated form of hPar1, which lacks the cyto-
plasmic tail, developed small or no tumors, similar to
cells expressing empty vector or control untreated cells
(25). This outcome highlights the role of signaling in
PAR1-induced breast cancer growth and development.
Indeed, antibody-array membranes revealed essential
hPar1 partners, including Etk/Bmx and Shc. The hier-
archy of binding, as well as the minimal binding region
in PAR1 C-tail, was established, rendering this region a
potential platform for therapeutic vehicles in breast
cancer.
Figure 5. Immunohistological staining of PAR1 in breast cancer tissue microarray. A) Representative images of positive PAR1
immunostaining in breast carcinoma tissue microarray (left, invasive lobular carcinoma; middle, ductal carcinoma in situ
[DCIS]; right, invasive ductal carcinoma [IDC]), as well as negative staining on sections of normal breast tissues. Histological
evaluation was carried out utilizing anatomical compartments of an ocular micrometer. Slide review was independently
performed by an expert pathologist (B.M.). The microscope was calibrated with a micrometer slide before each measurement.
All measurements were performed on the monitor screen using a 40 objective. On examining the sections, fields representing
tumor cells from the most cellular area at the center of the tumor were selected. Necrotic and inflammatory areas were avoided.
Five microscopic fields were screened. Ten cells/field were selected, and 50 cells/tumor case were assessed. Definition of a
tumor as PAR1
 was based on 25% staining of tumor cells (cutoff point of 25%). Immunostained tumor cells were chosen on
the basis of an initial overview of the cases to improve signal-to-noise ratios. Discrepancies were resolved by simultaneous
reexamination of the slides by both investigators (B.M. and Z.S.) using a double-headed microscope. Histological scoring was
based on the following: 1, 
25% positive cells (weak positive); 2, between 25 and 75% positive cells (moderate); 3, 75%
positive cells (strong). All controls were negative (0–5% positive cells). Extent of expression classified by score (1–3), number
of positive cells/field (x5). B) Immunohistological staining of PAR1 in breast cancer tissue microarray. Retrospective (5-yr)
analysis of ER tumors in women represented by the tissue microarray revealed that patients that express both ER and PAR1
exhibit a significantly shorter DFS (P0.006; median not reached) compared with ER but PAR1
 patients. C) OS of women
according to ER and PAR1 levels. Retrospective (5-yr) analysis of ER
 tumors in women represented by the tissue microarray
revealed a significantly shorter OS (P0.021; median not reached) compared with ER but PAR1
 women.
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Here we have demonstrated E2 responsiveness of the
hPar1 gene promoter and have found that exposure to
physiological concentrations of E2 induces hPar1 ex-
pression in breast carcinoma cells. The E2 effect on
hPar1 expression occurred in an ER
, but not in an
ER breast carcinoma cell line, and was inhibited by
the anti-E2 ICI 182,780, known to block responses
mediated through ER signaling (32). These data indi-
cate that the classic ER pathway is involved in transcrip-
tional activation of hPar1 rather than numerous alter-
native mechanisms of E2-regulated cell responses (34,
37, 38). Tamoxifen, the most widely used anti-E2 in
endocrine therapy of breast cancer, plays a dual role. It
can act as an antagonist at a high concentration,
inhibiting E2-induced hPar1 levels, whereas at physio-
logical concentrations it acts as an agonist for the
ER-inducing levels of hPar1 (unpublished results).
While we describe here a canonical mode of E2-
bound ER transcriptional activity (via binding to ERE
motifs present on the hPar1 promoter), noncanonical
E2 activation has also been described. ER can interact
with other transcription factors, through a process
referred to as transcription factor crosstalk. In this case,
ER can modulate the activities of other transcription
factors such as activator protein (AP)-1, nuclear fac-
tor-B (NF-B), or SP-1, by stabilizing their DNA bind-
ing and/or recruiting coactivators to the complex
(39–41). Another mechanism by which E2 and ER
affect gene expression has been termed the non-
genomic pathway. In this pathway, E2 binds to the ER
localized outside the cell nucleus (in the cytoplasm or
membrane). This, in turn, activates signal transduction
pathways in the cytosol, for example, MAPK signaling.
The AP-1 transcription factor, which acts through GC-
rich regions in the promoter, affects many growth
factor receptors, including IGF-1R, erbB 2, and EGFR,
leading to MAPK activation, which acts to phosphory-
late ER (Ser118) or ER coactivator phosphorylation,
thereby leading to increased ER activity (42, 43). PAR1,
once expressed, is known to activate the MAPK path-
way, hence contributing to improved ER transcriptional
activities. AP-binding motifs are in fact present in 4
different locations throughout the hPar1 promoter. It is
possible that once PAR1 is expressed by the canonical
ERE pathway, other mechanisms may also be involved.
These include transcription-factor crosstalk with AP-1,
or via the nongenomic activation signaling of the
MAPK pathway, which will enhance and improve ER
transcriptional activity (44–46).
E2-induced hPar1 could be particularly important in
the initial stages of breast cancer, when the majority of
breast tumors are reportedly ER (47, 48). Overexpres-
sion of hPar1 has also been observed in cases of ER
,
more violent tumors, whereby its level is controlled by
selective transcription-factors that come into view as
critical regulators. What these specific transcription
factors that regulate hPar1 overexpression in breast
cancer are is yet unknown. These aggressive tumors
that are E2 independent are resistant to traditional
anti-E2 therapy. In these tumors, high hPar1 levels, at
least in part, account for the more aggressive pheno-
type and poor prognosis. Consequently, while targeted
therapeutics toward PAR1 [e.g., SCH 530348, an oral
anti-PAR1 antagonist under phase 3 clinical evaluation
in patients with atherothrombotic disease (48, 49), or
pepducin, which inhibits PAR1 intracellular function
and the cell-penetrating inhibitory peptides, pep-
ducins] are not part of the oncologists’ list of protocols,
the presence of PAR1 identifies patients who may
require chemotherapy in addition to hormone treat-
ment. In addition, it may provide the basis for broad-
ening an oncologist’s therapeutic procedures. These
studies provide a guide to treatment decisions on
individual-based care. Furthermore, these inhibitors
may be considered for future therapeutic modality in
breast cancer.
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